Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **glucosamine-6-phosphate riboswitch ribozyme** (glmS ribozyme) is a catalytic RNA motif found in the 5′ untranslated region (UTR) of the mRNA encoding **glucosamine-6-phosphate synthetase** (GlmS), predominantly in Gram-positive bacteria[1][2][6][7]. This ribozyme uniquely combines characteristics of both a **riboswitch** (an RNA element that senses metabolite concentrations and alters gene expression) and a **ribozyme** (an RNA molecule with catalytic activity)[1][6]. It acts as a metabolite-activated, self-cleaving RNA, using the product of its own regulated gene (**glucosamine-6-phosphate; GlcN6P**) as a cofactor to trigger mRNA cleavage[1][2][3][5][7][8]. The result is negative feedback: when cellular GlcN6P is abundant, glmS ribozyme cleaves its host mRNA, reducing GlmS enzyme production and thus GlcN6P synthesis further[1][3][6]. Structurally, the ribozyme forms a compact tertiary structure with multiple pseudoknots and specifically binds GlcN6P, which acts in acid-base catalysis during RNA cleavage[1][3][5]. The ribozyme pre-folds into its active state before ligand binding, and GlcN6P does not induce gross conformational change, acting more as a true coenzyme than a classical allosteric ligand[1][3][5]. The glmS ribozyme is a well-established model for co-transcriptional gene regulation and is a potential target for novel antibiotics aimed at disrupting bacterial cell wall synthesis by interfering with mRNA stability of essential genes[4][7][6]. No clinically approved drugs directly target the glmS ribozyme, but inhibitors could, in theory, disrupt its regulatory feedback loop and impair bacterial viability, making it a candidate for antibacterial drug development[4][7].
Ligand-activated self-cleavage: The small molecule metabolite **glucosamine-6-phosphate** (GlcN6P) acts as a cofactor to trigger site-specific RNA self-cleavage, leading to mRNA degradation and decreased protein synthesis[1][2][3][4][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glucosamine-6-phosphate riboswitch ribozyme (glmS ribozyme).